To the Editor: Despite the reservations mentioned by Higby in an accompanying editorial,1 the study by Strauss and his colleagues2 (September 10 issue) provides convincing evidence that prophylactic granulocyte transfusions should not be used routinely during remission-induction therapy of acute myelogenous leukemia (AML). The Toronto Leukemia Study Group recently completed an investigation, similar to that of Strauss et al., of the role of prophylactic granulocyte transfusions in adults with acute nonlymphocytic leukemia. Sixty-seven patients were randomized to a prophylactic granulocyte transfusion or to a control group. Patients in both groups received standard remission-induction chemotherapy. (During the initial part of.
ASJC Scopus subject areas